Industry News

Zosano Pharma Corporation concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at No class has been certified in the above action."/>
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Zosano Pharma Corporation and Advises Investors With Losses in Excess of $10,000 Contact the Firm
American Renal Associates Holdings, Inc. concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at No class has been certified in the above action."/>
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of American Renal Associates Holdings, Inc. and Advises Investors With Losses to Contact the Firm
Insys Therapeutics deceptively marketed and sold Subsys-- a spray form of the prescription opioid drug fentanyl-- to physicians treating patients for conditions such as neck and back pain. "This drug company's desire for increased..."/>
Drugmaker pushed opioid cancer drug on patients with neck pain: state lawsuit [Chicago Tribune]
Aurora Spine Corporation announces financial results for the three months and six months ended June 30, 2016.. "In Q2 2016 we generated our highest quarterly revenue since our inception and saw an increase in revenue over Q1, which had previously been our highest revenue quarter to date," said Trent Northcutt, President and CEO of Aurora Spine. ""/>
Aurora Spine Corporation Files Condensed Consolidated Financial Statements for the 3 Months and Six Months Ended June 30, 2016
Impax Laboratories, Inc. announced today that the Company had issued a voluntary nationwide retail level recall on August 19, 2016 for one lot of Lamotrigine Orally Disintegrating Tablet 200 mg. The Company is issuing this press release to provide further heightened awareness of this recall and to provide instructions to consumers, pharmacists, and wholesalers in possession of the affected product. Details related to the recalled..."/>
Impax Laboratories, Inc. Issues Voluntary, Nationwide Recall for One Lot of Lamotrigine Orally Disintegrating Tablet 200 mg Due to the Potential for 100 mg Blister Cards being Packaged in 200 mg Containers
Amarin Corporation plc, announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland, provided notice that the Issuer has exercised its option to mandatorily exchange all $118.734 million in aggregate principal amount of its 3.50% May 2014 Exchangeable Senior Notes due 2032 into American Depositary Shares of Amarin, with each ADS representing one..."/>
Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in May 2014 and November 2015
Flex Pharma, Inc. announced today that W. Larry Kenney, Ph.D., Professor of Physiology and Kinesiology at Penn State University, has joined the Company’ s Scientific Advisory Board."/>
Flex Pharma Announces Scientific Advisory Board Appointment and Management Change
Sophiris Bio Inc., a biopharmaceutical company developing topsalysin for the treatment of urological diseases, today announced that it has closed its previously announced underwritten public offering. The terms of the completed offering are consistent with the terms which were outlined in the Company's press release on August 23, 2016.. Piper Jaffray& Co. is acted as sole book-running manager for the..."/>
Sophiris Bio Closes Underwritten Public Offering
Transition Therapeutics Inc. has received shareholder approval for a plan of arrangement involving Transition, US-based healthcare company Opko Health, Inc., Opko Global Holdings, Inc. and the Transition shareholder, the company said. On 30 June, the companies announced a deal under which Opko Health would acquire Transition Therapeutics. Under the terms of the agreement approved by the boards of directors of..."/>
Transition Therapeutics Wins Shareholder Nod for USD 60m Opko Health Buyout
Accenture, Johnson& Johnson, and PepsiCo. Women in the U.S. earn, on average, 79 cents for every dollar a man earns, according to Census Bureau data, and the gap is more pronounced for African-American and Native American women and..."/>
A-B signs White House's equal pay pledge [St. Louis Post-Dispatch]
Emergent BioSolutions Inc.. On June 22, 2016, Emergent revealed that the U.S. government had issued two official solicitation notices specifying that it would only be purchasing 29.4 million doses of the BioThrax vaccine from Emergent,..."/>
Purcell Julie & Lefkowitz LLP Is Investigating Emergent BioSolutions Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
ActiveCare, Inc., a provider of diabetes management products and wellness services for self-insured employers nationwide, has reported financial results for the third fiscal quarter ended June 30, 2016.. "We continue to make strong financial progress as we streamline the Company and better penetrate the market," stated Jeffrey Peterson, CEO and Chairman of ActiveCare. The Company reported total revenues of $2,176,000 for the quarter ended June 30, 2016..."/>
ActiveCare Announces Third Quarter Financial Results
Alere Inc., a global leader in rapid diagnostic tests, today issued the following statement in response to inquiries from its shareholders:. On August 25, 2016, Alere filed a complaint against Abbott in Delaware Chancery Court, which seeks to compel Abbott to fulfill its obligations under the terms of the merger agreement to take all actions necessary to promptly obtain all required anti-trust approvals. We expect the redacted version of..."/>
Alere Issues Statement
CytRx Corporation securities between November 18, 2014 and July 11, 2016, inclusive. CytRx investors have until September 23, 2016 to file a lead plaintiff motion. Investors suffering losses on their CytRx investments are encouraged to contact Casey Sadler of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to..."/>
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of CytRx Corporation Investors and Encourages Investors to Contact the Firm
American Renal Associates Holdings, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws. American Renal provides kidney dialysis services to patients across the country. According to recent news reports, and a complaint filed by UnitedHealth Group, Inc., the Company has allegedly steered patients away from Medicare and Medicaid programs into..."/>
Glancy Prongay & Murray LLP Commences Investigation on Behalf of American Renal Associates Holdings, Inc. Investors
Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, is pleased to announce that company management will present at the following investor conferences in September:. 2016 Wells Fargo Healthcare Conference. Date: Wednesday, September 7, 2016."/>
Cambrex to Present at Upcoming Investor Conferences in September
Lupin Ltd, the country's Mumbai-based third largest drug maker, said on Friday that it had received tentative approval from the United States Food and Drug Administration for its Paroxetine Extended-Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg. Lupin can now potentially market a generic version of Canada-based Apotex Technologies Inc.' s anti-depressant tablet Paxil CR tablets of the same dosage. When the patents or exclusivities granted to a brand-name..."/>
Lupin secures tentative FDA nod for anti-depressant drug Paxil [Mint, New Delhi]
Invacare Corporation announced that it declared a cash dividend of$. 0125 per share on its common shares and$. 011364 per share on its Class B common shares payable October 21, 2016 to shareholders of record on October 13, 2016.. Invacare Corporation, headquartered in Elyria, Ohio, is a global leader in the manufacture and distribution of innovative home and long-term care medical products that promote recovery and active lifestyles."/>
Invacare Declares Quarterly Dividend
Mettrum Health Corp.,, a vertically integrated provider of cannabis products, is pleased to announce that it has completed its previously announced bought deal offering of 5,661,000 common shares of the Company, at a price of $2.65 per Share for aggregate gross proceeds of $15,001,650."/>
Mettrum Health Corp. Closes $15 Million Bought Deal Offering of Common Shares

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary746 Articles
Information Technology697 Articles
Financials577 Articles
Health Care408 Articles
Industrials403 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at